期刊文献+

Effect of Prevention and Treatment of Murine Acute Viral Myocarditis and Protection of Lymphoid Organ Atrophy with Xinkang Oral Liquid(心康口服液)

原文传递
导出
摘要 Objective:The effect of prevention and treatment of Xinkang oral liquid(心康口服液,XKOL)on experimental coxsackievirus B_(3)(CVB_(3))myocarditis mice model were investigated.Methods:The mice were inoculated intraperitoneally with 0.3 ml of 105 TCID 50 of CVB_(3)to induce acute viral myocarditis model.These mice were divided into model control group(Group A),prevention high dosage group(Group B)and prevention low dosage group(Group C),treatment high dosage group(Group D)and treatment low dosage group(Group E),respectively.In addition,XKOL control group(Group F)and normal control group(Group G)were not infected with CVB_(3)intraperitoneally.The administration of XKOL in Group B and C began 2 days before virus infection.All animals were sacrificed on day 20 for evaluation.Results:Histological examination showed extensive myocardial necrosis and cell infiltration in most of Group A mice,but necrosis and cell infiltration were less severe in Group B,C,D and E mice.Thymus weight in Group B,C,D and E mice were heavier and less cell depletion occurred than those in Group A.Conclussion:The XKOL could effectively inhibit myocardial CVB_(3)replication,reduce the myocardial inflammatory response,lower incidence rate of myocarditis and prevent the disease associated lymphoid organ atrophy in this animal models.
作者 WAN Su-jun ZHAO Hong LI Jian-nong WANG Li-xia HUANG Xia-zhen CHEN Hong-shan 万素君;赵红;李建农;王丽霞;黄霞珍;陈鸿珊(The 2nd Department of Basic Medicine,Guang''anmen Hospital,China Academy of Traditional Chinese Medicine,Beijing(100053);Fuwai Hospital,Chinese Acad emy of Medical Sciences;Institute of Medical and Biological Technique,Chine se Academy of Medical Sciences)
出处 《Chinese Journal of Integrative Medicine》 SCIE CAS 2002年第1期48-50,共3页 中国结合医学杂志(英文版)
基金 Nature Science Foundion Committee Projects No.39770916
  • 相关文献

参考文献5

  • 1[1]GS Sainani, MP Dekate and CP Rao. Heart disease caused by coxsackie virus B infection. British Heart J 1975,37∶819.
  • 2[2]M Herzum, SA Huber, R Weller, et al. Treatment of experimental muri ne coxsackie B 3 myocarditis. Eur Heart J 1991;12(suppl D)∶220.
  • 3[3]C Kishimoto, CS Crumpacker, WH Abelmann. Prevention of murine co xsackie B 3 viral myocarditis and associated lymphoid organ atrophy with recomb inant human leukocyte interferon α A/D. Cardiovascular Res 1988;22∶732.
  • 4[4]NV Houten and SA Huber. Genetics of coxsackie B 3 myocarditi s. Eur Heart J 1991;12(Suppl D)∶108-112.
  • 5[5]D Matteucci, A Toniolo, PG Conaldi, et al. Systemic lymphoid a trophy in coxsackie virus B3 infected mice. J Infect Dis 1985;151∶110.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部